NanoViricides seeks DR Congo regulator clearance for Phase II Ebola trial of NV-387 oral gummies
NNVC•Outbreak backdrop in the DRC
The filing comes during the DRC’s 17th Ebola outbreak, with more than 930 deaths and nearly 2,400 confirmed cases in two months.
Clinical research organization named
The company named Om Sai Clinical Research as CRO; it is also running NanoViricides’ Phase II mpox trial in the DRC.
Regulatory filing for Phase II Ebola trial
NanoViricides filed with DRC regulator ACOREP seeking clearance to start a Phase II trial of NV-387 oral gummies for Bundibugyo Ebola.
